New Canadian dyslipidemia guidelines now recommend monitoring C-reactive protein in some patients
New Canadian dyslipidemia guidelines now recommend monitoring C-reactive protein in some patients.
High sensitivity C-reactive protein (hs-CRP) will be used to determine whether to treat moderate-risk patients who DON'T have high cholesterol.
High-risk patients almost always get statins...and low-risk patients rarely do unless they have very high cholesterol.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive